Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats

Psychopharmacology

Volumn 172, Issue 4, 2004, Pages 415-421

  Marona Lewicka, Danuta ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

5 HT1A; Aripiprazole; Drug discrimination; LY 293284; Rats; WAY 100635

Indexed keywords

ARIPIPRAZOLE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1 AGONIST; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG EFFECT; FOOD INTAKE; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SEROTONIN SYNDROME; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; MALE; PIPERAZINES; PYRIDINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; TRYPTAMINES;

EID: 2442547256     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1677-6     Document Type: Article

References (60)

1. 1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5
2. Andersen HL, Kilpatrick IC (1996) Prevention by (±)-8-hydroxy-2- (di-N-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. Br J Pharmacol 118:421-427
3. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334:141-147
4. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46
5. 2D-adrenoceptors in rat lumbar spinal cord. J Pharmacol Exp Ther 269:110-120
6. Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OH-DPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338:191-195
7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
8. Christoffersen CL, Meltzer LT (1998) Reversal of haloperidol-induced extrapiramidal side effects in cebus monkey by 8-hydroxy-2-(di-N-propylamino) tetralin and its enantiomers. Neuropsychopharmacology 18:399-402
9. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
10. 1A agonist LY 165163. Psychopharmacology 93:82-86
11. 2C receptors. Psychopharmacology 136:409-414
12. 2C receptors. Synapse 35:144-150
13. 1A receptors in human post-mortem brain. Eur J Pharmacol 386:313-315
14. Ferre S, Artigas F (1995) Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopaminereceptor-independent mechanism. Neurosci Lett 187:61-64
15. 1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 270:1270-1281
16. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88
17. Fujikawa M, Nagashima M, Inoue T, Yamada K, Furukawa T (1996) Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 53:903-909
18. Goodnick PJ, Jerry JM (2002) Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 3:1773-1781
19. 1A receptors in prefrontal cortex and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48:355-363
20. Hillegaart V, Magnusson O, Ahlenius S (2000) A9 and A10 dopamine nuclei as a site of action for effects of 8-OH-DPAT on locomotion in the rat. Pharmacol Biochem Behav 67:55-63
21. Hutson PH, Donohoe TP, Curzon G (1987) Neurochemical and behavioural evidence for an agonist action of 1-[2-(4-aminophenyl)ethyl]-4-(3- fluoromethylphenyl) piperazine (LY 165,163) at central 5-HT receptors. Eur J Pharmacol 138:215-223
22. Inoue T, Domae M, Yamada K, Furukawa T (1996) Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichorophenyl)-1-piperazinyl]butyloxy}-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137-143
23. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
24. 1A receptor. Eur J Pharmacol 441:137-140
25. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336
26. Joyce JN, Goldsmith SG, Gurevich EV (1997) Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. J Psychiatr Res 31:197-212
27. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33-40
28. 2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336
29. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interaction of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627
30. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-112
31. Marona-Lewicka D, Nichols DE (1994) Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol 258:1-13
32. 1A receptor-mediated behavioral effects ovelap its other properties in rats. Psychopharmacology 164:93-107
33. 1A receptors in human brain tissue. Eur J Pharmacol 221:397-398
34. McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40:885-887
35. 2-adrenoceptors. Eur J Pharmacol 97:151-155
36. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21[Suppl 2]:106S-115S
37. Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295:853-861
38. 1A receptor agonists in the spontaneous tail-flick paradigm. J Pharmacol Exp Ther 269:121-131
39. 1A receptors in vivo. J Pharmacol Exp Ther 273:1418-1427
40. Momiyama T, Amano T, Todo N, Sasa M (1996) Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 310:1-8
41. Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217
42. 1A/dopamine agonist. J Pharmacol Exp Ther 268:1304-1310
43. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312:35-44
44. Prinssen EP, Kleven MS, Koek W (1999) Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144:20-29
45. 1A receptors. Eur J Pharmacol 395:143-147
46. 1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav Pharmacol 11:299-305
47. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibited haloperidol-induced catalepsy. Eur J Pharmacol 453:217-221
48. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68:29-39
49. Ridley RM, Harder JA, Baker HF (1996) Neurochemical modulation of the hippocampus in learning, remembering and forgetting in primates. Neurodegeneration 5:467-471
50. Semba J, Watanabe A, Kito S, Toru M (1995) Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopamine mechanism in rat brain. Neuropharmacology 34:785-791
51. Shapiro DA, Renock S, Arrington E, Chiodo LA, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
52. Stahle L (1992) Do autoreceptors mediate dopamine agonist-induced yawning and suppression of exploration? A critical review. Psychopharmacology 106:1-13
53. Stahle L, Ungerstedt U (1990) Yawning and suppression of exploration induced by dopamine agonists: no relation to extracellular striatal levels of dopamine. Pharmacol Biochem Behav 35:204-209
54. 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708:209-214
55. 3H]lisuride labels free receptor and receptor coupled to G protein. J Neurochem 65:1909-1916
56. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511
57. Wadenberg ML (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339
58. Wadenberg ML, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat-enhancement of antipsychotic-like effects without catalepsy. J Neural Transm Gen Sect 83:43-53
59. 2 receptor activity. Schizophrenia Res 60[Suppl 1]:119
60. Yoshida K, Sugita T, Higuchi H, Hashikawa Y (1998) Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13:421-422